atomoxetine
A norepinephrine reuptake inhibitor non-stimulant medication used to treat ADHD in children and adults; brand name Strattera; the first non-stimulant ADHD medication approved by FDA
As defined in Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
Other definitions
A non-stimulant medication commonly known as Strattera used to treat ADHD by selectively inhibiting norepinephrine reuptake
Cognitive Disengagement Syndrome - What is it? How Does it Relate to ADHD?
Where it comes up · 2
- Rethinking ADHD Treatment: The Power of Non-Stimulant Medication8 claims
- Cognitive Disengagement Syndrome - What is it? How Does it Relate to ADHD?1 claim
Most important claims · 9 of 9Search all claims for “atomoxetine” →
- A 2023 comparative study found that viloxazine (Qelbree) was more effective than atomoxetine (Strattera) and worked faster, showing effects within about one week for children and two weeks for adults.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) and viloxazine (Qelbree) are both norepinephrine reuptake inhibitors that work by increasing norepinephrine in the prefrontal cortex, which secondarily increases dopamine and serotonin in that brain region.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) can take a month or more to reach good therapeutic effect.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Unlike stimulants, atomoxetine (Strattera) and viloxazine (Qelbree) must be taken daily because they require consistent dosing to maintain their effects.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Some studies show that atomoxetine (Strattera) produces measurable improvement in CDS symptoms that can be statistically separated from improvement in ADHD symptoms, supporting CDS as a distinct treatable condition.Cognitive Disengagement Syndrome - What is it? How Does it Relate to ADHD?
- Viloxazine (Qelbree) is still a brand-name medication, which means doctors often need to complete insurance authorizations for coverage, and some insurances require patients to try and fail atomoxetine (Strattera) first before approving viloxazine.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) was the first non-stimulant medication approved for ADHD in both children and adults in 2002, making it over 20 years old as a treatment option.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- There are currently four FDA-approved non-stimulant medications for ADHD: clonidine (Kapvay), guanfacine (Intuniv), atomoxetine (Strattera), and viloxazine (Qelbree, approved in 2021).Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Based on Dr. Marks' clinical experience, atomoxetine (Strattera) produced only so-so results in adult patients, with stimulants always seeming to work better and faster.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication